Review
History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results

https://doi.org/10.1016/S1386-6532(09)70002-2Get rights and content

ABSTRACT

Twenty years have passed since the first studies using human papillomavirus (HPV) testing began in clinical settings. At that time controversy regarding the role of HPV in cervical carcinogenesis still divided the scientific world. Epidemiological and natural history studies on HPV and cervical cancer in the ensuing two decades secured the necessary role of high-risk (carcinogenic) HPV in the genesis of cervical cancer, providing the rationale for testing for its cause. Subsequently, cross sectional studies and large randomized trials have provided clinical validation for high-risk HPV testing in triage of atypical squamous cells of undetermined significance (ASC-US), in postcolposcopy management of women referred for ASC-US, atypical squamous cells “cannot rule out high grade” (ASC-H), atypical glandular cells “not otherwise specified” (AGC NOS) and low grade squamous intraepithelial lesion (LSIL) and not found to have cervical intraepithelial neoplasia (CIN) 2+ or adenocarcinoma in situ (AIS) at initial colposcopy, in post-treatment of CIN 2+ surveillance, and in cotesting with the Papanicolaou (Pap) test of women age 30 and over. This is the story of the road traveled that brought the clinical use of HPV testing from its genesis only a few years after Dr. zur Hausen's discovery to its present eminent role in both primary cervical cancer screening and abnormal Pap management.

References (59)

  • J Cuzick et al.

    Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

    Vaccine

    (2008)
  • EP Dixon et al.

    Isolation of RNA from residual BD SurePath liquid-based cytology specimens and detection of HPV E6/E7 mRNA using the PreTectt HPV-Proofer assay

    J Virol Methods

    (2008)
  • J Dockter et al.

    Clinical performance of the APTIMA® HPV Assay for the detection of high-risk HPV and high-grade cervical lesions

    J Clin Virol

    (2009)
  • LL Villa

    Assessment of new technologies for cervical cancer screening

    Lancet Oncol

    (2008)
  • F Carozzi et al.

    Use of p16-INK4A overexpression to increase the specifi city of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial

    Lancet Oncol

    (2008)
  • M Dürst et al.

    A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions

    Proc Natl Acad Sci USA

    (1983)
  • M Boshart et al.

    A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer

    EMBO J

    (1984)
  • A Meisels et al.

    Condylomatous lesions of the cervix and vagina. I. Cytologic patterns

    Acta Cytol

    (1976)
  • E Schwarz et al.

    Structure and transcription of human papillomavirus sequences in cervical carcinoma cells

    Nature

    (1985)
  • J Zhou et al.

    Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles

    Virology

    (1992)
  • JA Tidy et al.

    A new and sensitive method of screening for human papillomavirus infection

    Obstet Gynecol

    (1989)
  • R Reid et al.

    Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection

    Am J Obstet Gynecol

    (1991)
  • JT Cox et al.

    An evaluation of human papillomavirus testing as part of referral to colposcopy clinics

    Obstet Gynecol

    (1992)
  • National Cancer Institute Workshop

    Thea 1988 Bethesda System for reporting cervical/vaginal cytologic diagnosis

    J Am Med Assoc

    (1989)
  • JT Cox

    Editorial. Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings

    J Am Med Assoc

    (1999)
  • M Schiffman et al.

    ASCUS LSIL Triage Study. Design, methods and characteristics of trial participants

    Acta Cytol

    (2000)
  • D Solomon et al.

    Comparison of HPV testing, repeat cytology, and immediate colposcopy in ASCUS triage: baseline results from a randomized trial

    J Natl Cancer Inst

    (2001)
  • The ASCUS LSIL Triage Study (ALTS)* Group

    Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance

    Am J Obstet Gynecol

    (2003)
  • TC Wright et al.

    2001 ASCCP-Sponsored Consensus Conference. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities

    JAmMed Assoc

    (2002)
  • Cited by (66)

    • Immunotherapy in cervix cancer

      2020, Cancer Treatment Reviews
    • Commercially available molecular tests for human papillomaviruses: a global overview

      2020, Clinical Microbiology and Infection
      Citation Excerpt :

      For comprehensive control, including recently announced efforts to eliminate cervical cancer, two key prevention strategies are available: vaccination against human papillomaviruses (HPVs) and effective screening programmes followed by treatment of detected precancerous and cancerous lesions [1–8].

    • Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening

      2019, International Journal of Infectious Diseases
      Citation Excerpt :

      As HPV cannot be cultured, current tests for HPV infection rely on the detection of viral nucleic acids in the infected region. HPV DNA analysis is conducted as an adjunctive test for all cervical cytology samples in women over 30 years of age according to current recommendations (Cox, 2009). Pap smear and HPV DNA testing are currently the methods most widely applied in screening for cervical lesions, but both methods are limited by a low specificity and lack of association with patient prognoses (Schiffman and Solomon, 2009).

    View all citing articles on Scopus
    View full text